{
    "ticker": "RPTX",
    "name": "Repare Therapeutics Inc.",
    "description": "Repare Therapeutics Inc. is a clinical-stage precision oncology company dedicated to transforming the lives of patients with cancer. Founded in 2016 and headquartered in Montreal, Canada, Repare is at the forefront of developing innovative therapeutics targeting DNA damage response (DDR) pathways. The company's unique approach leverages its proprietary platform, which identifies and exploits vulnerabilities in cancer cells, particularly those driven by genetic mutations. Repare's lead product candidate, RP-3500, is an oral therapeutic designed to treat tumors with specific genetic alterations, including those with BRCA mutations. With a robust pipeline of candidates in various stages of development, Repare continues to advance its mission of delivering targeted therapies that improve patient outcomes. The company aims to provide novel treatment options for patients with solid tumors, particularly those who have limited available therapies. Repare\u2019s commitment to scientific excellence and collaboration with leading research institutions positions it as a key player in the evolving landscape of cancer treatment.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Montreal, Quebec, Canada",
    "founded": "2016",
    "website": "https://www.reparetherapeutics.com",
    "ceo": "Lisa L. McGregor",
    "social_media": {
        "twitter": "https://twitter.com/RepareTx",
        "linkedin": "https://www.linkedin.com/company/repare-therapeutics/"
    },
    "investor_relations": "https://investors.reparetherapeutics.com",
    "key_executives": [
        {
            "name": "Lisa L. McGregor",
            "position": "CEO"
        },
        {
            "name": "Danielle D. Brill",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "RP-3500"
            ]
        }
    ],
    "seo": {
        "meta_title": "Repare Therapeutics Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Repare Therapeutics Inc., a leader in precision oncology focused on developing targeted therapies for cancer patients. Learn about our pipeline and mission.",
        "keywords": [
            "Repare Therapeutics",
            "Precision Oncology",
            "Cancer Treatment",
            "RP-3500",
            "DNA Damage Response"
        ]
    },
    "faq": [
        {
            "question": "What does Repare Therapeutics focus on?",
            "answer": "Repare Therapeutics focuses on developing precision oncology therapies targeting DNA damage response pathways in cancer."
        },
        {
            "question": "Who is the CEO of Repare Therapeutics?",
            "answer": "Lisa L. McGregor is the CEO of Repare Therapeutics Inc."
        },
        {
            "question": "Where is Repare Therapeutics headquartered?",
            "answer": "Repare Therapeutics is headquartered in Montreal, Quebec, Canada."
        },
        {
            "question": "What is RP-3500?",
            "answer": "RP-3500 is Repare Therapeutics' lead product candidate aimed at treating tumors with specific genetic alterations."
        },
        {
            "question": "When was Repare Therapeutics founded?",
            "answer": "Repare Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "CLVS",
        "MRNA",
        "XLRN",
        "PTGX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "ABBV"
    ]
}